Are Liquid Biopsies Ready for the Clinic?
Sophisticated blood tests offer a less invasive way to characterize cancers, guide treatment and catch recurrences sooner, but tissue biopsies remain the gold standard. Read More…
On Being Asked Not to Tell: Hiding Illness From Loved Ones
Keeping her grandfather’s cancer a secret from him felt counterintuitive to Tina Chai as a teen, but conversations with other Chinese Americans helped her understand the reasons Chinese physicians and families may practice cancer nondisclosure. Read More…
Cancer and COVID-19 Vaccination
Amid continued research showing the impact of COVID-19 on people with cancer, patients are asking when they should get a COVID-19 vaccine. Most health care providers are familiar with triage, the careful and intentional orchestration of patient care to ensure that those who have the most severe injuries or illnesses get Read more…
Radiotherapy For Rectal Cancer Linked To Risk For Later Malignant Gynecological Neoplasms
Women who receive radiotherapy for rectal cancer may be at an increased risk of uterine and ovarian cancer, a new study suggests. In an analysis of information from the SEER database on more than 20,000 female patients diagnosed with rectal cancer, researchers found the treatment was associated with a three-fold Read more…
FDA Approves Osimertinib for Adjuvant EGFR-Mutated Lung Cancer
The FDA has approved the use of osimertinib as a treatment for patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). According to a release from the manufacturer, the approval is for patients who have had tumor resection with curative intent and was made under the Read more…
Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer
Antitumor activity was observed in the study population. Dose modifications of cabozantinib improve long-term tolerability. Biomarkers are needed to identify patient populations most likely to benefit. Further study of cabozantinib with or without panitumumab in patients with metastatic colorectal cancer is warranted. Read More…
Activity of Sorafenib Plus Capecitabine in Previously Treated Metastatic Colorectal Cancer
Treatment for patients with metastatic colorectal cancer (mCRC) typically involves multiple lines of therapy with eventual development of treatment resistance. In this single arm, phase II study involving heavily pre-treated patients, the combination of sorafenib and capecitabine (SorCape) yielded a clinically meaningful progression free survival of 6.2 months with an Read more…